Which drugs go off patent in 2029?
Five blockbuster drugs with about $34.7B in 2025 worldwide sales lose US exclusivity in 2029, led by Darzalex (Johnson & Johnson, $14.3B). All five are biologics that face biosimilars.
| Drug | Company | Area | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Darzalex | Johnson & Johnson | Oncology | $14.3B | Patent-expiry estimate | In clinical trials | – |
| Ocrevus | Roche | Neuroscience | ≈$8.4B | Patent-expiry estimate | In clinical trials | – |
| Cosentyx | Novartis | Immunology | $6.7B | Patent-expiry estimate | In clinical trials | 2028 · pending |
| Repatha | Amgen | Cardiometabolic | $3.0B | Patent-expiry estimate | No US filing found | – |
| Enbrel | Amgen | Immunology | $2.2B | Settlement / court date | Approved, waiting to launch | 2026 · −67% |
One of these dates is fixed by a launch, settlement, court ruling or company guidance; four are estimates from patent expiry and could move. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Johnson & Johnson | Darzalex | $14.3B | 15% |
| Roche | Ocrevus | ≈$8.4B | 11% |
| Novartis | Cosentyx | $6.7B | 12% |
| Amgen | Repatha and Enbrel | $5.3B | 14% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Biosimilars usually erode a biologic's sales more gradually, because they are harder to make and switching takes longer. Cosentyx and Enbrel were also selected for Medicare price negotiation, which can cut Medicare revenue before or alongside US copies.
US exclusivity can end earlier or later than these dates if a court ruling, settlement or new patent changes the picture. See what happened to sales after past patent cliffs →